C. Chouaïd

17.9k total citations · 1 hit paper
500 papers, 7.2k citations indexed

About

C. Chouaïd is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, C. Chouaïd has authored 500 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 325 papers in Pulmonary and Respiratory Medicine, 256 papers in Oncology and 81 papers in Epidemiology. Recurrent topics in C. Chouaïd's work include Lung Cancer Treatments and Mutations (237 papers), Lung Cancer Diagnosis and Treatment (114 papers) and Cancer Immunotherapy and Biomarkers (87 papers). C. Chouaïd is often cited by papers focused on Lung Cancer Treatments and Mutations (237 papers), Lung Cancer Diagnosis and Treatment (114 papers) and Cancer Immunotherapy and Biomarkers (87 papers). C. Chouaïd collaborates with scholars based in France, United States and Germany. C. Chouaïd's co-authors include A. Vergnenègre, I. Monnet, Gilles Hejblum, Olivier Bylicki, Fabrice Barlési, Marie Wislez, Serge Adnot, Jean‐Baptiste Assié, Florian Guisier and Bernard Maître and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

C. Chouaïd

455 papers receiving 7.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

2013 489 citations Julien Mazières, Alexis B. Cortot et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
C. Chouaïd	4.6k	3.5k	923	904	737	500	7.2k
Jeffrey Crawford	2.8k 0.6×	6.8k 1.9×	834 0.9×	1.4k 1.5×	731 1.0×	206	10.2k
Karen H. Antman	3.3k 0.7×	3.5k 1.0×	551 0.6×	1.2k 1.3×	809 1.1×	146	8.4k
Mieke Van Hemelrijck	2.4k 0.5×	2.3k 0.6×	834 0.9×	1.3k 1.4×	1.4k 1.9×	364	7.8k
Simone Mathoulin‐Pélissier	1.6k 0.4×	2.0k 0.6×	853 0.9×	394 0.4×	756 1.0×	179	5.9k
Eleanor McFadden	3.2k 0.7×	5.0k 1.4×	1.0k 1.1×	865 1.0×	874 1.2×	13	10.1k
Ryan Woods	4.0k 0.9×	2.9k 0.8×	697 0.8×	1.4k 1.5×	1.7k 2.4×	116	8.9k
Olivier Mir	2.8k 0.6×	2.9k 0.8×	655 0.7×	1.2k 1.3×	610 0.8×	287	6.4k
Martin J. Edelman	4.3k 0.9×	4.6k 1.3×	544 0.6×	2.0k 2.2×	946 1.3×	302	8.7k
Massimo Di Maïo	3.9k 0.8×	5.1k 1.5×	1.0k 1.1×	2.0k 2.2×	1.4k 1.9×	403	9.3k
Barnett S. Kramer	2.5k 0.5×	2.9k 0.8×	1.3k 1.4×	1.2k 1.3×	1.1k 1.4×	114	7.9k

Countries citing papers authored by C. Chouaïd

Since Specialization

Citations

This map shows the geographic impact of C. Chouaïd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Chouaïd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Chouaïd more than expected).

Fields of papers citing papers by C. Chouaïd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Chouaïd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Chouaïd. The network helps show where C. Chouaïd may publish in the future.

Co-authorship network of co-authors of C. Chouaïd

This figure shows the co-authorship network connecting the top 25 collaborators of C. Chouaïd. A scholar is included among the top collaborators of C. Chouaïd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Chouaïd. C. Chouaïd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chouaïd, C., D. Debieuvre, Clarisse Audigier-Valette, et al.. (2025). Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis. Frontiers in Oncology. 15. 1526931–1526931. 1 indexed citations

Greillier, Laurent, Florian Guisier, Catherine Daniel, et al.. (2025). Real-world efficacy and safety of amivantamab in EGFR exon-20-mutant non-small cell lung cancer in a French early-access program: Amexon 20 GFPC study. Lung Cancer. 209. 108766–108766.

Chouaïd, C., et al.. (2024). The impact of KRAS mutational status on patient-reported outcomes in advanced non-small-cell lung cancer: a cross sectional study in France and Germany. Journal of Medical Economics. 28(1). 13–24. 2 indexed citations

Planchard, David, Nathalie Cozic, Marie Wislez, et al.. (2024). ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome.. Journal of Clinical Oncology. 42(16_suppl). 8501–8501. 6 indexed citations

Guisier, Florian, Charles Ricordel, Seyyid Baloglu, et al.. (2024). Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort. Current Oncology. 31(3). 1656–1666. 2 indexed citations

Fallet, Vincent, et al.. (2023). PDL1-status predicts primary resistance of metastatic, EGFR-mutated non small cell lung cancers to EGFR tyrosine-kinase inhibitors. Respiratory Medicine and Research. 84. 101018–101018. 5 indexed citations

Sebbag, E., et al.. (2023). 2179P Prospective monitoring of autoimmune events in cancer immunotherapy patients: A report on the first 658 patients in the PRAISE study. Annals of Oncology. 34. S1129–S1129. 1 indexed citations

Audigier-Valette, Clarisse, Thomas Filleron, D. Debieuvre, et al.. (2023). Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapy. Respiratory Medicine and Research. 84. 101012–101012. 5 indexed citations

Heudel, Pierre-Étienne, Anne Montfort, D. Debieuvre, et al.. (2023). Reduced risk of secondary primary extra pulmonary cancer in advanced/metastatic lung cancer patients treated with immune checkpoint inhibitors. Lung Cancer. 182. 107280–107280.

10.

Descourt, R., M. Pérol, David Planchard, et al.. (2022). Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study. Cancers. 14(7). 1751–1751. 5 indexed citations

11.

Chouaïd, C., R. Corre, Matteo Giaj Levra, et al.. (2022). Machine Learning–Based Analysis of Treatment Sequences Typology in Advanced Non–Small-Cell Lung Cancer Long-Term Survivors Treated With Nivolumab. JCO Clinical Cancer Informatics. 6(6). e2100108–e2100108. 6 indexed citations

12.

Avrillon, Virginie, Catherine Daniel, Pierre Boisselier, C. Le Péchoux, & C. Chouaïd. (2022). Nationwide Real-Life Safety and Treatment Exposure Data on Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III, Locally Advanced, Non-small Cell Lung Cancer: Analysis of Patients Enrolled in the French Early Access Program. Lung. 200(1). 95–105. 10 indexed citations

13.

Chouaïd, C., Michael Thomas, D. Debieuvre, et al.. (2022). Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts. Cancers. 14(24). 6148–6148. 3 indexed citations

14.

Gounant, V., M. Duruisseaux, Olivier Bylicki, et al.. (2021). Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients. Cancers. 13(5). 1040–1040. 9 indexed citations

15.

Bylicki, Olivier, F. Rivière, Florence Canouï‐Poitrine, et al.. (2020). Factors Associated With Aggressiveness of End-of-Life Care for Lung Cancer Patients and Associated Costs of Care. Clinical Lung Cancer. 22(3). e320–e328. 10 indexed citations

16.

Tordrup, David, C. Chouaïd, Pim Cuijpers, et al.. (2017). PRIORITIES FOR HEALTH ECONOMIC METHODOLOGICAL RESEARCH: RESULTS OF AN EXPERT CONSULTATION. International Journal of Technology Assessment in Health Care. 33(6). 609–619. 6 indexed citations

17.

Schmid‐Bindert, Gerald, Walburga Engel-Riedel, Martin Reck, et al.. (2015). A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer. Lung Cancer. 90(3). 397–404. 9 indexed citations

18.

Salaün, Mathieu, C. Chouaïd, V. Gounant, et al.. (2013). Cost-effectiveness of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for the preoperative staging of lung cancer, results from the French prospective multicenter trial "EVIEPEB". European Respiratory Journal. 42(Suppl 57). 1997–1997.

19.

Pérol, M., C. Chouaïd, David Pérol, et al.. (2012). Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 30(28). 3516–3524. 166 indexed citations

20.

Gary‐Bobo, Guillaume, Marco Alifano, Élisabeth Marcos, et al.. (2011). Pulmonary Artery Smooth Muscle Cell Senescence Is a Pathogenic Mechanism for Pulmonary Hypertension in Chronic Lung Disease. Circulation Research. 109(5). 543–553. 114 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact